Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
118.46
+2.60 (2.24%)
May 29, 2026, 4:00 PM EDT - Market closed
Palvella Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 206.39 | 57.98 | 83.6 | 7.35 | 38.64 | 117.76 |
Short-Term Investments | 55.46 | - | - | - | 20.53 | - |
Cash & Short-Term Investments | 261.85 | 57.98 | 83.6 | 7.35 | 59.17 | 117.76 |
Cash Growth | 246.25% | -30.64% | 1037.44% | -87.58% | -49.76% | 67.19% |
Accounts Receivable | - | - | 0.36 | - | 5.81 | 3.31 |
Other Receivables | - | - | 1.98 | - | 5.23 | - |
Total Trade Receivables | - | - | 2.34 | - | 11.04 | 3.31 |
Other Current Assets | 1.38 | 1.01 | 2.3 | 0.2 | 3.21 | 6.55 |
Total Current Assets | 263.23 | 58.99 | 88.23 | 7.55 | 73.42 | 127.63 |
Net Property, Plant & Equipment | - | - | - | - | 20.7 | 23.03 |
Other Long-Term Assets | - | - | - | - | 1.37 | 2.9 |
Total Assets | 263.76 | 59.56 | 88.23 | 7.55 | 95.49 | 153.56 |
Accounts Payable | 5.44 | 4.6 | 4.59 | 0.94 | 4.15 | 8.61 |
Accrued Expenses | 3.46 | 4.35 | 5.47 | 1.42 | 10.75 | 16.84 |
Current Portion of Leases | 0.21 | 0.2 | - | - | 0.86 | - |
Unearned Revenue | - | - | - | - | 20.82 | 25.12 |
Other Current Liabilities | - | 2.2 | 1.98 | - | - | - |
Total Current Liabilities | 9.12 | 11.34 | 12.04 | 2.36 | 36.58 | 50.56 |
Long-Term Leases | 0.38 | 0.43 | - | - | 12.24 | 13.84 |
Other Long-Term Liabilities | 21.96 | 19.8 | 13.59 | 9.07 | 18.73 | 38.4 |
Total Long-Term Liabilities | 22.33 | 20.23 | 13.59 | 9.07 | 30.98 | 52.24 |
Total Liabilities | 31.45 | 31.58 | 25.63 | 11.43 | 67.56 | 102.81 |
Preferred Stock | - | - | - | 70.6 | - | - |
Common Stock | 0.01 | 0.01 | 0.01 | - | 0.07 | - |
Additional Paid-in Capital | 383.42 | 163.34 | 156.33 | 1.82 | 318.53 | - |
Accumulated Other Comprehensive Income | 0.1 | 0.08 | 0 | - | -0.25 | - |
Retained Earnings | -151.22 | -135.45 | -93.74 | -76.3 | -290.42 | - |
Shareholders' Equity | 232.31 | 27.98 | 62.61 | -74.48 | 27.93 | 50.76 |
Total Liabilities & Equity | 263.76 | 59.56 | 88.23 | 7.55 | 95.49 | 153.56 |
Total Debt | 0.58 | 0.63 | 0 | 0 | 13.1 | 13.84 |
Net Cash (Debt) | 261.27 | 57.35 | 83.6 | 7.35 | 46.07 | 103.92 |
Net Cash Growth | 355.58% | -31.40% | 1037.44% | -84.05% | -55.67% | 90.67% |
Net Cash Per Share | 22.27 | 5.10 | 37.56 | 4.10 | 25.68 | 128.80 |
Book Value | 232.31 | 27.98 | 62.61 | -74.48 | 27.93 | 50.76 |
Book Value Per Share | 19.80 | 2.49 | 28.13 | -41.52 | 15.57 | 62.91 |
Tangible Book Value | 232.31 | 27.98 | 62.61 | -74.48 | 27.93 | 50.76 |
Tangible Book Value Per Share | 19.80 | 2.49 | 28.13 | -41.52 | 15.57 | 62.91 |